Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Internal Trade, which was founded in 1582. After sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in pharmaceutical manufacturing, pharmaceutical research and development, pharmaceutical wholesale and retail, chain hospitals and other fields.
contents
1 introduction
2 origin
3 historical achievements
4 business performance
5 leading products
6 honors won by listed companies
7
8 share reform
9 corporate culture
business purpose
philosophy
values < p. Ma Yinglong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Ma Yinglong Pharmaceutical") [1] is a time-honored Chinese enterprise with a history of more than 4 years
Ma Yinglong
, which was founded in 1582 (ten years of Wanli in Ming Dynasty). In 1582, Ma Jintang, the founder of Ma Yinglong, opened a small eye medicine shop, Ma Yinglong Shengji Pharmacy, in Dingxian County, Hebei Province (now Dingzhou City, Hebei Province), and created "eight treasures" eye drops. During the Qianlong period of Qing Dynasty, Ma Yinglong, a descendant of Ma Jintang, named "Babao Eye Drops" as "Dingzhou Eye Drops in Ma Yinglong". For more than 4 years, the brand of Ma Yinglong has been handed down from generation to generation, and it has written a legendary story of "saving the world with a wonderful hand and caring heart".
After the enterprise moved to Wuhan in p>1919, Ma Yinglong Shengji Pharmacy developed other series of products, and its production and operation developed rapidly. It was awarded national awards by the Ministry of Agriculture and Commerce and the Ministry of Railways at that time, and its products enjoyed a high reputation among Chinese in Southeast Asia, making it one of the first four enterprises in China to export goods overseas.
after the founding of the People's Republic of China, Ma Yinglong Shengji Pharmacy became a wholly state-owned enterprise-Wuhan No.3 Pharmaceutical Factory. In 1993, it was restructured into Wuhan Ma Yinglong Pharmaceutical Co., Ltd., and in 1995, it was controlled by china baoan Group, one of the earliest listed companies in China. On May 16th, 28, the company name was changed to "Ma Yinglong Pharmaceutical Group Co., Ltd." after deliberation and approval at the 27 Annual General Meeting of Shareholders.
2 Origin
has a long history. In the process of sorting out the history of "Ma Yinglong" by us and our predecessors, we have never been able to find historical materials and physical evidence related to the origin of Ma Yinglong. As for the origin of Ma Yinglong, we can only know from the folk legends that Ma Jingbiao, the ancestor of the Ma family in Wanli period of Ming Dynasty, completed the creation of eye drops in Dingzhou, Hebei Province. Therefore, for the time being, we will designate the Wanli period of the Ming Dynasty as the origin of Ma Yinglong's prescription for ophthalmic drugs, that is, Ma Shi's prescription for ophthalmic drugs.
during the Ming and Qing dynasties, the handicraft industry followed the tradition that the font size was named after my father. This tradition was followed in the formation and development of Ma Yinglong. Ma Wanxing adopted the name of his father Ma Yinglong as the brand name at the end of Qing Dynasty, and moved from Dingzhou, Hebei Province to Xiheyan, Qianmen, Beijing to open the "Beijing Ma Yinglong Eye Pharmacy" in the first year of Guangxu, Qing Dynasty. Since then, Xiheyan, Beijing has always been the center of the inheritance and production of Ma Yinglong eye medicine.
Later, Mary (Li) Pavilion, the son of Ma Wanxing, realized that consumers only recognize the number of words and don't recognize people, because Tongrentang always kept its name, and decided to break the tradition after inheriting the Ma Yinglong Eye Pharmacy in Beijing, and continue to use "Ma Yinglong" as the name for generations. Therefore, it can be said that it was the breakthrough and innovation of Mary Pavilion and its understanding of brand value that established and finally adopted the brand of "Ma Yinglong". [2]
3 Historical Achievements
Beijing is an important development place of ophthalmic drugs in Ma Yinglong. The history of "Ma Yinglong" is also the history with Beijing Ma Yinglong Eye Pharmacy as the main line.
According to records, Mary (Li Ting), the successor, located Beijing Ma Yinglong Eye Pharmacy at No.52 Xiheyan, Qianmen, Beijing in 1923 (the present store site still exists, and the plaque is faintly visible
). Since 193, Ma Yinglong Ophthalmology has been sold to Tianjin, Nanjing, Shanghai, Zhenjiang, Anhui, Henan, Hubei, Hunan, Jiangsu and other provinces and cities by setting up branches and mailing, achieving a breakthrough of < P > Ma Yinglong Ophthalmology's large-scale promotion to the whole country with Beijing Ma Yinglong Ophthalmology Pharmacy as the center, and handling the export certificate to Europe through the recommendation of Mr. Wu Linge, a good friend, in Shanghai, and taking the lead in creating the overseas export of traditional Chinese medicine ophthalmology.
During its operation, Beijing Ma Yinglong Ophthalmology has made remarkable achievements: in May of 5, 2, it won the third prize of the Ministry of Agriculture and Commerce Award; In 24 years of the Republic of China, he won the certificate of Excellence in the Ministry of Industry, and in the same year, he won the first prize in the national exhibition of goods produced along the railways of the Ministry of Railways; In 25 years of the Republic of China, he won the Nanjing government excellent prize; In 26 years, he won the medal of Panama Expo in San Francisco, USA.
Beijing Ma Yinglong not only achieved good business results through the efficacy of drugs, but also won the recognition of China traditional Chinese medicine and even oriental culture from westerners. Root
According to the official website of Princeton University, American engineer Moore
Gest, the donor of the Gest Oriental Library of Princeton University, used Ma Yinglong eye drops to treat his eye diseases during his stay in Beijing around 193s and achieved good results. This prompted him to purchase a batch of traditional medical books from China, which became the first collection of East Asian Library of Princeton University in the future.
4 Operating Performance
Ma Yinglong
By introducing the advanced operating mechanism and concept of Baoan Group in 1995, Ma Yinglong Pharmaceutical entered the fast lane of coordinated development. And established Jilin Ma Yinglong Pharmaceutical Co., Ltd., Sichuan Ma Yinglong Pharmaceutical Co., Ltd. and Wuhan Ma Yinglong Pharmaceutical Co., Ltd.. Over the past ten years, Ma Yinglong Pharmaceutical has carried out fruitful property right system reform, formed diversified ownership structure and relatively perfect corporate governance structure, and continuously introduced advanced management methods, management mechanisms and ideas. Ma Yinglong Pharmaceutical adheres to the brand management strategy, takes the market as the guide, strengthens the core competitiveness, integrates social resources with the brand as the link, meets customer needs, cultivates customer loyalty, and keeps pace with the times under the banner of the brand; Adhere to the strategy of capital management, based on industrial management, and take capital management as a means of extraordinary development; Adhere to the alliance management strategy and establish a win-win alliance and cooperation relationship with upstream and downstream, domestic and foreign partners; Insist on integrating heavy historical resources and long-standing traditional concepts with innovative thinking. The modern management consciousness and the cultural tradition of Ma Yinglong pharmaceutical industry, which has been formed for more than 4 years, have formed an interactive effect, which has triggered the vitality of Ma Yinglong, and various economic indicators have been rising year by year, maintaining a positive growth of more than double digits for ten consecutive years.
The production capacity, sales capacity and profitability of Ma Yinglong Pharmaceutical have all increased by more than 1 times, and the operating net assets have increased by nearly 5 times. Over the past ten years, the facilities and working environment of various equipments have undergone fundamental changes, and the renovation rate has reached 1%. Over the past decade, the income of employees has increased by 3-18 times, and the number of jobs provided has quadrupled. Over the past ten years, the accumulated tax paid by Ma Yinglong Pharmaceutical reached 5 million yuan, and the shareholders' rights and interests increased by more than 5 times. Ma Yinglong pharmaceutical industry ranks first in Hubei province in terms of economic benefits, and is the first brand in the field of hemorrhoid drugs in China. By December 31st, 25, the company's total assets reached 8 million yuan, and its asset-liability ratio was only about 2%.
the company has passed the GMP (good manufacturing practice) and GSP (Good Manufacturing Practices) certification of the State Food and Drug Administration as a whole, and has taken the lead in obtaining the certification of ISO141, an environmental management system, and OHSAS181, an occupational safety and health management system issued by international authorities in the pharmaceutical industry. We have established a perfect marketing system and a nationwide sales network, and our products are exported to Southeast Asia, Europe and America. Ma Yinglong pharmaceutical brand reputation is growing, and it has become the leading brand in the field of hemorrhoid drugs in China. Wuhan Ma Yinglong Pharmacy Chain Co., Ltd. is the first pharmaceutical retail enterprise in Hubei Province to obtain GSP certificate, and is gradually growing into a famous brand of pharmaceutical retail in Central China. The technical strength and integration ability of drug research and development have been gradually improved, and the national first-class new drug "Guanfu A Hydrochloride" has been successfully developed, and long-term strategic cooperation relations have been established with many scientific research institutions, and it has been awarded the post-doctoral workstation site by the Ministry of Personnel.
Despite the rapid growth of pharmaceutical business in Ma Yinglong, the overall gross profit margin of the pharmaceutical wholesale and retail sectors continues to decline, which has limited contribution to the company's profits.
5 leading products
Ma Yinglong
The leading products in the pharmaceutical industry are Ma Yinglong Musk Hemorrhoids Ointment, Ma Yinglong Musk hemorrhoids suppository, Compound Glycyrrhiza Mixture and other drugs, and their hemorrhoid-treating drugs have always been in the leading position among similar drugs in the domestic market, and the exclusive skin drugs Longzhu Ointment and Qiying Neixiao Ointment are also well-known. In 26, the company accelerated the introduction of a series of new drugs for treating hemorrhoids, such as oral (tablets, granules, capsules, etc.), injection, fumigation and washing, physical instruments, etc., forming the characteristics of diversified varieties and serialized products.
The company's market share of hemorrhoid drugs in OTC remained above 5%, with a market share of
26%. Among them, musk hemorrhoid ointment basically monopolized the market of this dosage form, accounting for more than 8% in OTC market, and its sales scale still has the potential to grow. There is a great demand for hemorrhoid treatment and antitussive drugs in the domestic market, while the leading products of the company, such as Ma Yinglong Musk Hemorrhoid Cream and Compound Glycyrrhiza Mixture, are of good quality and high market popularity. Matching with hemorrhoid treatment products, the company plans to set up 5-8 chain anorectal hospitals nationwide in 8-1 years. Ma Yinglong Dragon Ball Ointment was transformed from the secret recipe handed down by Ma Yinglong family, but it was in short supply because of its good curative effect in clinical stage. Because dermatosis is a common and frequently-occurring disease in China, the annual drug cost of skin diseases in China is about 6 million yuan, so it can be predicted that this product has a broad market prospect. In 26, it became the only "China Famous Trademark" in the field of hemorrhoids in China, with a brand value of 2.813 billion yuan.
6 listed companies
Ma Yinglong
Ma Yinglong Pharmaceutical has developed into a professional and multi-functional pharmaceutical group listed company (stock code: 6993) involved in pharmaceutical production, pharmaceutical research and development, pharmaceutical wholesale and retail, etc., with 1 subsidiaries.
In p>24, Ma Yinglong shares were successfully listed on the Shanghai Stock Exchange, which achieved the goal of capital securitization in Ma Yinglong, marking a new historical development stage for Ma Yinglong. The listing of Ma Yinglong stock further strengthened the core competitiveness of Ma Yinglong Pharmaceutical, enhanced the brand image of Ma Yinglong Pharmaceutical, and provided a channel for sustained and rapid development of Ma Yinglong Pharmaceutical, a platform for standardized and healthy operation. Since its listing, Ma Yinglong Pharmaceutical Co., Ltd. has been well received by investors for its good business performance and growth, and the proportion of institutional investors' shares is quite high. In 24 (1.3 yuan/share) and 25 (1.17 yuan/share), it ranked first among listed pharmaceutical companies in Shanghai and Shenzhen and listed companies in Hubei Province.
7 Honors
Ma Yinglong
Ma Yinglong Pharmaceutical Co., Ltd. has been recognized by the state and local governments as a "high-tech enterprise", a "backbone enterprise in the modern industrial base of traditional Chinese medicine", "enterprise with superior quality", "enterprise with advanced economic benefits" and "China's 1 most respected listed companies", and has been praised as a "successful model of state-owned enterprise reform". Ma Yinglong brand was rated as "China 5 Most Valuable Brands" (Ma Yinglong ranked 2th in the list of China's most valuable brands in 26 with a brand value of 2.831 billion yuan), and became the only recommended brand for hemorrhoid medication by China Anorectal Association. Ma Yinglong brand was rated as a well-known trademark in China, Ma Yinglong musk hemorrhoid ointment was rated as the best-selling product in the same industry for many times, and musk hemorrhoid suppository was included in the national torch plan.
8 share reform
Ma Yinglong
Wuhan Ma Yinglong Pharmaceutical Group Co., Ltd. was established on May 9, 1994 and registered in Wuhan Administration for Industry and Commerce. The company, formerly known as Wuhan No.3 Pharmaceutical Factory, was approved by the Wuhan Economic System Reform Commission in the document "Wu Ti Gai [1993] No.189" and was established by directional fundraising. On March 2, 24, with the approval of China Securities Regulatory Commission's Notice on Approving the Public Offering of Wuhan Ma Yinglong Pharmaceutical Group Co., Ltd. (Z.J.F.Zi. (24) No.4), the company publicly issued 18 million shares of RMB common stock, which was listed on the Shanghai Stock Exchange on May 17, 24. After this issuance, the company's share capital increased to 51,169,74 shares, including 9 million state shares, 23,578,88 legal person shares, 59,86 individual shares and 18 million ordinary RMB shares. On August 13th, 24, Wuhan Hua Han Investment Management Co., Ltd. and Wuhan Donghu Innovation and Technology Investment Co., Ltd. signed the Contract for Transfer of Legal Person Shares. Wuhan Hua Han Investment Management Co., Ltd. transferred its 2.6 million legal person shares held by the company to Wuhan Donghu Innovation and Technology Investment Co., Ltd. at a price of 9.41 yuan per share.
honorary certificates obtained by Ma Yinglong (5)
On March 19th, 25, Wuhan Donghu Innovation Technology Investment Co., Ltd. transferred its 3.8 million legal person shares (accounting for 7.43% of the total share capital of the company) to Wuhan Hua Han Investment Management Co., Ltd., the shareholder of the company, and completed the registration and transfer procedures for the transfer of legal person shares on June 3rd, 25.
on July 19th, 26, the company implemented the share-trading reform, with the number of tradable shares changed from 18 million to 21.6 million, and the number of non-tradable shares changed from 33,169.74 million to 29,569.74 million.
On May 19th, 27, the profit distribution plan for 26 was approved by the 26 annual general meeting of shareholders. Based on the total share capital of 51,169,74 at the end of 26, 2 shares were distributed to 3 yuan for every 1 shares (including tax), and the share capital of the company was changed to 61,43,688 shares, including 35,483,688 shares with restricted sale conditions.
on may 16th, 28, the company was reviewed and approved by the 27 annual general meeting of shareholders, and its name was changed to
Ma Yinglong pharmaceutical group co., ltd .. The corresponding industrial and commercial approval and industrial and commercial change procedures for the change of company name have all been completed. On May 3th, 28, the company obtained a new business license of < P > in Wuhan Administration for Industry and Commerce, and the new official seal came into use on June 2nd, 28. Securities abbreviation remains unchanged.
9 corporate culture
business purpose
create health for customers, create wealth for shareholders
create opportunities for employees and create benefits for society
Ma Yinglong
Essence: The essence of business purpose is to enable various stakeholders to obtain sustainable, fair and maximized benefits through the operation of Ma Yinglong, thus forming a stable platform for interest relations.
logic: by